KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Share-based Compensation (2016 - 2025)

Quest Diagnostics (DGX) has disclosed Share-based Compensation for 17 consecutive years, with $25.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 7.41% to $25.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $88.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $88.0 million for FY2025, 0.0% changed from the prior year.
  • Share-based Compensation hit $25.0 million in Q4 2025 for Quest Diagnostics, up from $20.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $27.0 million in Q4 2024 to a low of $16.0 million in Q2 2023.
  • Historically, Share-based Compensation has averaged $20.4 million across 5 years, with a median of $20.0 million in 2024.
  • Biggest five-year swings in Share-based Compensation: plummeted 44.12% in 2021 and later soared 42.11% in 2024.
  • Year by year, Share-based Compensation stood at $19.0 million in 2021, then grew by 15.79% to $22.0 million in 2022, then decreased by 13.64% to $19.0 million in 2023, then skyrocketed by 42.11% to $27.0 million in 2024, then decreased by 7.41% to $25.0 million in 2025.
  • Business Quant data shows Share-based Compensation for DGX at $25.0 million in Q4 2025, $20.0 million in Q3 2025, and $21.0 million in Q2 2025.